Psychiatry

Psychosis, Substance Use and Eating Disorders: An MCCQE Review

This page covers how the MCCQE tests psychosis, substance use disorders, opioid agonist therapy, alcohol withdrawal, cannabis and eating disorders. You get the decision points that decide marks, the Canadian guidance behind them, five original practice questions, flashcards and a study plan.

Most tested
First-episode psychosis work-up, antipsychotic adverse effects, opioid agonist therapy, alcohol withdrawal, medical instability in anorexia
Guideline to know
CRISM national guidelines for opioid use disorder and alcohol use disorder; Canada's Guidance on Alcohol and Health
Classic trap
Choosing withdrawal management alone for opioid use disorder instead of opioid agonist therapy
Study time
8-10 hours, plus mixed question blocks

What the MCCQE tests in psychosis and substance use

These topics carry a lot of acute care. A young man is brought in by police with new paranoid beliefs. A surgical patient becomes tremulous on day two. A woman is found unresponsive with pinpoint pupils. A teenager faints in gym class and turns out to weigh far less than she should. The MCCQE wants a physician who can keep these patients safe, find the medical cause that mimics a psychiatric one, and start the treatment that Canadian guidance supports.

Chronic care items test long-term antipsychotic monitoring, opioid agonist therapy, relapse prevention for alcohol use disorder and the follow-up of eating disorders. Health promotion items test screening and brief intervention for alcohol and cannabis, naloxone distribution and lower-risk use advice. Psychosocial care is everywhere: housing, stigma, the justice system, family involvement and harm reduction.

Communication and professional behaviour items in this area test non-judgmental language, motivational interviewing, confidentiality with adolescents, reporting duties such as fitness to drive, and capacity when a patient refuses care.

  • Assessment: duration rules for psychotic disorders, organic causes of psychosis, withdrawal timelines, medical instability in eating disorders
  • Management: antipsychotic choice and monitoring, opioid agonist therapy, benzodiazepines for alcohol withdrawal, refeeding
  • Safety: overdose reversal, delirium tremens, NMS, refeeding syndrome
  • Communication: motivational interviewing, harm reduction, involving family

Schizophrenia and first-episode psychosis

Duration separates the diagnoses. Brief psychotic disorder lasts at least a day and less than a month. Schizophreniform disorder lasts one to six months. Schizophrenia needs at least six months of disturbance with at least one month of active symptoms such as delusions, hallucinations or disorganized speech, plus a decline in function. Schizoaffective disorder needs a period of psychosis without mood symptoms, alongside major mood episodes for most of the illness. Delusional disorder has non-bizarre delusions with otherwise well-preserved function.

A first episode needs a medical and substance work-up before the label. Look for delirium (fluctuating attention, disorientation), drugs such as stimulants, cannabis, steroids and dopamine agonists, alcohol or sedative withdrawal, and medical causes including thyroid disease, infection, autoimmune encephalitis, seizures and brain lesions. Reasonable first tests include CBC, electrolytes, glucose, kidney and liver function, TSH, a urine drug screen and, depending on risk, HIV and syphilis serology. Brain imaging is guided by neurological signs, atypical features or older age at onset.

Treatment starts with a second-generation antipsychotic at a low dose, chosen by side-effect profile and patient preference, combined with psychosocial support through an early psychosis intervention program where available. After a first episode, treatment is usually continued for an extended period because relapse is common when medication stops. Long-acting injectable antipsychotics help when adherence is a problem.

Clozapine is the drug for treatment-resistant schizophrenia, usually defined as failure of two adequate antipsychotic trials, and it also lowers suicide risk. It needs regular neutrophil monitoring for agranulocytosis and attention to myocarditis early in treatment, seizures, sialorrhea and severe constipation that can progress to ileus.

  • Metabolic monitoring for every antipsychotic: weight, waist, blood pressure, glucose or A1C, lipids
  • Acute dystonia in a young man after haloperidol: anticholinergic such as benztropine
  • Akathisia: lower the dose or switch; propranolol can help
  • Tardive dyskinesia: late, often persistent; review the need for the drug
  • NMS: fever, lead-pipe rigidity, autonomic instability, confusion, high CK. Stop the antipsychotic and give supportive care

Substance use disorders: screening, brief intervention and harm reduction

The MCCQE expects you to ask every adult about alcohol, tobacco, cannabis and other drugs, to use non-stigmatizing language, and to match the intervention to readiness. Motivational interviewing uses open questions, reflections and the patient's own reasons for change. In a stem where the patient is not ready, the best answer is usually to explore ambivalence and keep the door open, not to lecture or discharge them.

Canada's Guidance on Alcohol and Health, published by the Canadian Centre on Substance Use and Addiction, describes risk as a continuum. Two standard drinks or fewer a week is low risk, three to six is moderate risk, and seven or more carries increasingly high risk. A Canadian standard drink contains 13.45 g of pure alcohol. The guidance is much stricter than the older low-risk limits that many IMGs learned, and stricter than many US resources, so watch for it in counselling items.

Harm reduction is mainstream Canadian practice. Take-home naloxone kits are available without a prescription. Supervised consumption services operate in several provinces under federal exemptions. The Good Samaritan Drug Overdose Act protects people who call 911 at an overdose from some possession charges. Exam answers that support these measures fit Canadian practice.

Opioid use disorder and opioid agonist therapy

Opioid toxicity presents with reduced consciousness, slow or shallow breathing and small pupils. The first action is airway and ventilation support with naloxone. Naloxone may wear off before long-acting opioids, so observation is required, and the unregulated drug supply in Canada is dominated by fentanyl and its analogues, sometimes mixed with sedatives that naloxone does not reverse.

For opioid use disorder, the CRISM national guideline recommends buprenorphine-naloxone as the preferred first-line treatment when appropriate, because of its safety profile and flexible take-home dosing. Methadone is the alternative when buprenorphine-naloxone is not suitable or has not worked. Slow-release oral morphine is an option for selected patients when first-line treatments have not worked. Withdrawal management alone, without moving to long-term treatment, is not recommended because it raises the risk of overdose death once tolerance falls.

Starting buprenorphine is an exam favourite. A full agonist must have worn off enough that the patient is in moderate withdrawal before the first dose, or the partial agonist will precipitate withdrawal. Withdrawal scales such as COWS guide timing. Low-dose start approaches, sometimes called microdosing, avoid the need for withdrawal and are increasingly used with fentanyl, but the exam usually tests the classic rule.

Pregnancy is not a reason to stop opioid agonist therapy. Abrupt withdrawal in pregnancy is harmful, and agonist treatment is the standard. Naltrexone is not a first-line agent for opioid use disorder and must not be started while opioids are in the system.

Starting buprenorphine-naloxone: the decision path

  1. 1Confirm opioid use disorderTake a full history: substances, route, overdoses, last use. Offer naloxone and safer-use advice the same day.
  2. 2Offer agonist therapy firstBuprenorphine-naloxone is preferred first-line when suitable. Withdrawal management alone is not treatment.
  3. 3Check timing of last full agonistFentanyl and methadone linger. Starting too early precipitates withdrawal.
  4. 4Score withdrawal (e.g. COWS)Give the first dose in moderate withdrawal, or use a low-dose start that overlaps the full agonist.
  5. 5Titrate and review closelyAdjust over the first days, see the patient often, and plan take-home doses as stability grows.
  6. 6Switch if not workingMethadone, or slow-release oral morphine in selected patients, when buprenorphine is not suitable.
The order the exam expects for a patient with opioid use disorder who wants treatment.

Alcohol withdrawal and alcohol use disorder

Withdrawal starts within hours of the last drink with tremor, sweating, anxiety, nausea and tachycardia. Withdrawal seizures usually occur within the first two days, alcoholic hallucinosis with a clear sensorium can appear in the same window, and delirium tremens typically starts after two to three days with confusion, agitation, hallucinations, fever and autonomic instability. Delirium tremens can be fatal and needs monitored care.

Benzodiazepines are the treatment. Symptom-triggered dosing guided by the CIWA-Ar scale uses less drug than fixed schedules in patients who can communicate. Long-acting agents such as diazepam give a smoother course. Lorazepam or oxazepam are preferred in significant liver disease or in older patients because they do not rely on hepatic oxidation. Give thiamine before glucose to any patient at risk of Wernicke encephalopathy, which presents with confusion, ataxia and eye movement problems, though the full triad is often absent.

For alcohol use disorder, the CRISM guideline on high-risk drinking and alcohol use disorder recommends naltrexone or acamprosate as first-line medications, alongside psychosocial treatment. Naltrexone must not be used in patients taking opioids or in acute hepatitis or liver failure. Acamprosate needs dose adjustment in kidney impairment. Disulfiram is not a first-line choice. Other agents such as topiramate and gabapentin are alternatives in specific situations.

  • Seizure in withdrawal: treat with benzodiazepines; phenytoin does not prevent alcohol withdrawal seizures
  • Haloperidol alone is not treatment for alcohol withdrawal and can lower the seizure threshold
  • Driving: provinces have rules about reporting patients whose substance use makes driving unsafe

Red flags that change the answer

Red flagFever and rigidity on an antipsychoticThink NMS: stop the antipsychotic, check CK and renal function, give supportive care in a monitored bed.
Red flagConfusion 2 to 3 days after the last drinkDelirium tremens: high-dose benzodiazepines, fluids, thiamine and close monitoring.
AdmitWithdrawal plus a prior seizurePast withdrawal seizures or DTs predict severe withdrawal. Admit and treat with benzodiazepines early.
ObserveSedated after naloxoneSuspect a co-ingested sedative or long-acting opioid. Support the airway and observe.
AdmitHeart rate under 50 in anorexiaBradycardia, hypotension, syncope or electrolyte disturbance mean medical instability and admission.
SafetyCommand hallucinations to harmAssess risk to self and others now. The provincial mental health act may be needed.
Spot these in a stem and the safe answer is usually admission, monitoring or an urgent drug change.

Cannabis and eating disorders

Non-medical cannabis has been legal for adults in Canada since October 2018 under the Cannabis Act, with provincial rules on age and sale. Legal does not mean harmless. Canada's Lower-Risk Cannabis Use Guidelines advise delaying first use, choosing lower-THC products, avoiding smoking, avoiding daily use and never driving after use. Heavy use of high-THC products, especially in adolescence, is linked to psychosis, and cannabis use worsens the course of schizophrenia.

Cannabinoid hyperemesis syndrome causes cyclical vomiting in heavy long-term users, who often report relief with hot showers. The cure is stopping cannabis. Edible ingestion by young children causes drowsiness, ataxia and sometimes respiratory depression and is a recurring presentation since legalization. Cannabis use disorder is treated with psychosocial approaches such as CBT and motivational enhancement.

Anorexia nervosa is restriction leading to significantly low weight, with fear of weight gain and a disturbed view of body shape. Bulimia nervosa is recurrent binge eating with compensatory behaviour at normal or higher weight. Binge eating disorder has binges without regular compensation. ARFID is restriction without body image concern. The MCCQE tests medical risk more than psychology: bradycardia, hypotension with orthostatic change, hypothermia, arrhythmia, electrolyte problems, syncope and acute food refusal are reasons for hospital admission, and the Canadian Paediatric Society lists admission criteria for adolescents.

Refeeding syndrome happens when nutrition restarts after starvation. Phosphate, potassium and magnesium fall as insulin drives them into cells, and heart failure, arrhythmia and death can follow. Monitor these electrolytes closely in the first days and replace them. Family-based treatment is first-line for adolescents with anorexia. CBT adapted for eating disorders is first-line for bulimia and binge eating disorder, and fluoxetine is used in bulimia. Bupropion is contraindicated in bulimia and anorexia because of seizure risk.

Canadian practice points and differences from US practice

Several answers differ from US-based resources. Slow-release oral morphine is a recognized Canadian option for opioid agonist therapy in selected patients and is not part of standard US practice. In 2018 Health Canada removed the requirement for a federal exemption to prescribe methadone, and buprenorphine-naloxone is prescribed in primary care across Canada, with training rules set by provincial colleges. Naloxone kits are free through many provincial programs and pharmacies.

Cannabis is federally legal in Canada, so counselling focuses on lower-risk use, driving and youth, not on legal consequences. Canada's 2023 alcohol guidance sets much lower thresholds than US dietary guidelines. Early psychosis intervention programs exist in most provinces, and a referral to one is a strong answer after a first episode. Involuntary admission and treatment are governed by provincial mental health acts, and the rules on treating a capable patient against their wishes differ between provinces, so the exam tests the principles of capacity and risk rather than forms.

Canadian answers versus common US-resource habits

Canadian practice

  • Buprenorphine-naloxone preferred first-line per CRISM
  • Slow-release oral morphine is an option for selected patients
  • No federal exemption needed to prescribe methadone or buprenorphine
  • Alcohol risk counselled with Canada's Guidance on Alcohol and Health
  • Adult cannabis use legal; counsel with lower-risk guidelines

Common US or other-system habit

  • Methadone and buprenorphine presented as equal first choices
  • Slow-release oral morphine not part of standard practice
  • Questions built around special prescriber waivers
  • Higher weekly drink limits from dietary guidelines
  • Counselling framed around legal consequences of use
Where IMGs trained on US material most often pick the wrong option.

How to read psychosis and substance stems

Start with the vital signs. Fever, tachycardia and confusion in a patient on an antipsychotic suggest NMS. Fever, agitation and confusion two to three days after admission in a heavy drinker suggest delirium tremens. Bradycardia and hypothermia in a thin adolescent mean medical instability. Pinpoint pupils with slow breathing mean opioid toxicity. These cues tell you that the question is about safety first.

Then check the timeline. How long has the psychosis lasted? When was the last drink or the last opioid dose? When did refeeding begin? Many questions turn on timing alone. Finally, read the lead-in. 'Next step' in an acute stem is usually stabilization or a safety action. 'Long-term management' in a substance stem usually means opioid agonist therapy or an anti-craving drug plus psychosocial care, not detox alone.

  • New psychosis in a 60-year-old: think medical, neurological or drug cause first
  • Rigidity plus fever on an antipsychotic: NMS; clonus plus hyperreflexia on serotonergic drugs: serotonin syndrome
  • Patient in early opioid withdrawal asking for buprenorphine: wait for moderate withdrawal or use a low-dose start

Stimulants, sedatives, tobacco and mixed toxicity

Cocaine and methamphetamine cause a sympathomimetic picture: agitation, tachycardia, hypertension, dilated pupils, sweating and hyperthermia. Chest pain after cocaine needs an ECG and troponin because coronary vasospasm and infarction occur in young people. Benzodiazepines are the first drug for agitation and sympathetic overdrive, with active cooling for hyperthermia. The classic exam answer avoids starting a beta-blocker alone in acute cocaine toxicity. Methamphetamine can also cause a psychosis that looks like schizophrenia; it usually settles with abstinence, and persistence beyond the expected washout period should make you reconsider a primary psychotic disorder.

Benzodiazepine dependence matters because withdrawal can cause seizures and delirium, much like alcohol. The safe answer is a slow, planned taper, often after switching to a longer-acting agent, never abrupt cessation. In older adults the exam favours deprescribing because benzodiazepines raise the risk of falls, fractures, motor vehicle collisions and cognitive impairment. Combining benzodiazepines with opioids or alcohol increases the risk of fatal respiratory depression, and naloxone does not reverse the benzodiazepine part.

Tobacco is the substance that kills the most Canadians, and the MCCQE expects you to treat it as a chronic disease. Ask about use at every visit, advise quitting clearly, and offer both counselling and medication. First-line medications are nicotine replacement therapy, varenicline and bupropion. Combining a long-acting patch with a short-acting form such as gum or lozenge works better than a single form. People with schizophrenia smoke at high rates and benefit from the same treatments. Remember that smoking induces CYP1A2, so stopping smoking can raise clozapine and olanzapine levels and cause toxicity.

Mixed toxicity is the rule in the current Canadian drug supply. Fentanyl is often combined with benzodiazepine-type drugs or with the veterinary sedative xylazine. A patient who starts breathing after naloxone but stays sedated may have a non-opioid sedative on board, so keep supporting the airway rather than giving ever larger naloxone doses. Xylazine is also linked with severe chronic wounds in people who inject.

  • Cocaine chest pain: ECG, troponin, benzodiazepines, cooling if hot
  • Benzodiazepine dependence: slow supervised taper, never sudden stop
  • Smoking cessation: counselling plus NRT, varenicline or bupropion
  • Quitting smoking raises clozapine levels: monitor for toxicity
  • Sedated after naloxone with normal breathing: suspect a co-ingested sedative

Lab, ECG and imaging points the stems rely on

Urine drug screens are a common trap. Standard opiate immunoassays detect morphine and codeine but often miss synthetic opioids such as fentanyl, methadone and oxycodone, which need specific tests. A negative opiate screen in a patient with obvious opioid toxicity does not change management. Drug screens are also not a condition of starting or continuing opioid agonist therapy in the punitive sense: they support clinical care and safe take-home dosing decisions, and a positive result should start a conversation, not end treatment.

Methadone prolongs the QTc. An ECG is reasonable at baseline in patients with risk factors and after dose increases into higher ranges, and other QT-prolonging drugs such as some antipsychotics, antiemetics and antibiotics add risk. Haloperidol and several other antipsychotics also prolong the QTc, which matters in delirium and agitation stems.

For alcohol, a raised gamma-glutamyl transferase, macrocytosis and an AST higher than ALT support heavy use but never make the diagnosis alone. Low magnesium and phosphate are common in admitted drinkers. Wernicke encephalopathy presents with confusion, eye movement abnormalities and ataxia, although most patients do not have all three. Give parenteral thiamine to any at-risk patient before or with glucose, and do not wait for the full triad.

Eating disorders have their own lab pattern. Purging by vomiting causes hypokalemia, low chloride and metabolic alkalosis, and sometimes a raised salivary amylase. Laxative misuse can cause metabolic acidosis. Restriction causes bradycardia, hypotension, hypothermia, hypoglycemia and, in severe cases, low white cells. Phosphate may be normal at admission and then fall with refeeding, which is why daily electrolytes matter in the first days. A first episode of psychosis with focal signs, atypical features or older age calls for neuroimaging, and delirium with fever calls for an infection and metabolic work-up.

  • Negative opiate screen does not rule out fentanyl or methadone
  • Methadone plus another QT-prolonging drug: check the ECG
  • Thiamine before or with glucose in anyone at risk of Wernicke
  • Vomiting: hypokalemic metabolic alkalosis; laxatives: acidosis is possible

Communication, capacity and the law in these topics

Psychiatric emergencies raise questions about consent and involuntary care. Each province and territory has its own mental health act. The details differ, but the common thread is that a person can be held for assessment, and later admitted involuntarily, when a mental disorder puts them or others at risk of serious harm, or in some provinces at risk of serious deterioration. Involuntary admission does not automatically mean the person lacks capacity to consent to treatment. Capacity is decision-specific and must be assessed separately, and provincial law sets out who decides for a patient who is found incapable.

Confidentiality questions are frequent. A young adult with psychosis may not want family told about the diagnosis. You can listen to family without disclosing information, and you should encourage the patient to involve them. Disclosure without consent is allowed or required in limited situations, such as an imminent risk of serious harm to an identifiable person, reportable conditions, and child protection. For driving, provincial rules require or permit physicians to report patients whose medical condition, including substance use or active psychosis, makes driving unsafe. Tell the patient you are reporting.

Language is part of care. Use person-first terms such as person who uses drugs or person with an alcohol use disorder, not addict or abuser. Stigma drives people away from treatment, and the exam rewards non-judgmental wording in counselling options. A pregnant patient who uses substances should be offered treatment and support, and a report to child welfare is required only when you have reasonable grounds to believe a child is or may be in need of protection under provincial law, not because of substance use alone.

Adolescents raise their own issues. A capable adolescent can consent to their own care in most provinces, and confidentiality applies to them, with the usual safety exceptions. In an eating disorder, an adolescent who is medically unstable and refuses admission may need the provincial legal route for involuntary care, and the parents are usually central partners in family-based treatment.

  • Involuntary admission and capacity to consent to treatment are separate decisions
  • Listen to family freely; disclose only with consent or a legal exception
  • Report unsafe drivers as provincial law requires, and tell the patient
  • Substance use in pregnancy is not by itself a reason to call child welfare

How the MCCQE frames these topics: three mini cases

Case one. A 67-year-old woman with no psychiatric history is brought in by her son because she has believed for a week that neighbours are poisoning her water. She is disoriented to date, her attention drifts, and she was started on a new medication for bladder symptoms last month. The tempting answer is an antipsychotic and a psychiatry referral. The expected answer is to treat this as delirium until proven otherwise: review medications, especially anticholinergics, check for infection, electrolytes, glucose and other medical causes, and examine for neurological signs. New psychosis late in life is medical until shown otherwise.

Case two. A 38-year-old man on methadone comes to the emergency department after a fall. He was given his usual dose in hospital, and he asks for his take-home doses so he can leave. The exam is testing safe continuity: confirm the dose with the community prescriber or pharmacy before giving it, never double a dose because a patient reports missing one, and arrange communication with the prescriber at discharge. Missed doses of methadone over several days may need a dose reduction because tolerance falls quickly.

Case three. A 19-year-old university student is seen after vomiting repeatedly for two days. She has had similar episodes every few months for a year, gets relief from long hot showers and smokes cannabis daily. Her labs show a mild hypokalemia. The tempting answer is a full GI work-up and repeated antiemetics. The expected answer is to recognize cannabinoid hyperemesis syndrome, rehydrate, replace potassium, and explain that stopping cannabis is the definitive treatment, using motivational interviewing rather than a lecture.

How these topics show up in NAC stations

If you will also sit the NAC Examination, these topics appear as history, counselling and management stations. Common tasks include taking a substance use history from a patient admitted for another reason, counselling a patient who wants help with opioids, assessing a patient with new hallucinations, and talking to a parent about a teenager who is losing weight. In each, the examiner looks for a structured, non-judgmental history and a clear safety plan.

A strong substance history covers each substance, the amount, route, frequency, last use, withdrawal history, overdose history, injection practices and harm reduction, past treatment, effect on work and relationships, legal issues, and readiness to change. Always ask about suicidal thoughts in a patient with psychosis, depression or heavy substance use, and about access to means. In a psychosis station, ask about command hallucinations and thoughts of harming others, assess insight, and screen for medical and drug causes.

Oral questions at the end often test exactly the decision points on this page: the first-line treatment for opioid use disorder, the drug for alcohol withdrawal, the electrolytes to monitor in refeeding, or the next step for a patient refusing admission. Practise answering them in one or two clear sentences.

  • Substance history: what, how much, how, last use, withdrawal, overdose, harms, readiness
  • Always screen for suicide and violence risk in psychosis and heavy use
  • Offer naloxone and safer-use advice in any opioid station
  • Close with a specific follow-up plan, not a vague referral

A one-week revision plan for this topic

If you have a week, spread this subject over seven short sessions rather than one long day. Day one: psychotic disorder durations, the first-episode work-up and antipsychotic adverse effects. Day two: NMS, serotonin syndrome, clozapine monitoring and metabolic monitoring. Day three: opioid toxicity, naloxone, opioid agonist therapy and buprenorphine starts. Day four: alcohol withdrawal timeline, CIWA-Ar logic, Wernicke encephalopathy and alcohol use disorder medications. Day five: stimulants, benzodiazepines, tobacco and cannabis, including cannabinoid hyperemesis and pediatric edible ingestions. Day six: eating disorders, admission criteria and refeeding syndrome. Day seven: a timed mixed block from this question bank, then review every wrong answer and write down the rule you missed.

Keep one page of numbers you are sure of, such as the psychotic disorder durations and the alcohol withdrawal timeline, and one page of rules, such as treat opioid use disorder with agonist therapy and give thiamine before glucose. Rules win more marks than numbers in this subject.

Psychosis and substance use: presentations, key actions and traps
PresentationKey clueFirst action or first-line treatmentCommon wrong answer
First-episode psychosisNew delusions or hallucinations, any ageMedical and drug work-up, then low-dose second-generation antipsychoticTreating without excluding delirium or drugs
Treatment-resistant schizophreniaTwo adequate antipsychotic trials failedClozapine with neutrophil monitoringA third ordinary antipsychotic
Neuroleptic malignant syndromeFever, rigidity, autonomic instability, high CKStop the antipsychotic, supportive careAdding another antipsychotic for agitation
Opioid toxicityLow consciousness, slow breathing, miosisAirway, ventilation, naloxone, observationDischarge soon after one naloxone dose
Opioid use disorderCraving, loss of control, withdrawalBuprenorphine-naloxone; methadone if unsuitableWithdrawal management alone
Alcohol withdrawalTremor, sweating, tachycardia within hours to daysSymptom-triggered benzodiazepine plus thiamineHaloperidol alone
Alcohol use disorderOngoing harmful drinkingNaltrexone or acamprosate plus psychosocial careDisulfiram as first choice
Cannabinoid hyperemesisCyclical vomiting eased by hot showersStop cannabis, supportive careRepeated imaging and surgery referral
Anorexia with instabilityBradycardia, hypotension, hypothermia, low potassiumAdmit, monitor, cautious refeeding with electrolyte checksOutpatient care only

Worked examples in MCCQE style

Pick an answer to see why each option is right or wrong. These examples are written for this page; the bank holds the full set for psychosis & substance use.

Example 1

A 29-year-old man asks his family physician for help with daily use of smoked fentanyl for the past 2 years. He has had two non-fatal overdoses. His last use was 16 hours ago. He is yawning and sweating, with dilated pupils, rhinorrhea and piloerection, and scores in the moderate range on the COWS. Liver enzymes are normal. He is not pregnant or taking other medications.

What is the most appropriate next step?

Show answer and reasoning

Answer: C. Start buprenorphine-naloxone now

  • A. Withdrawal management alone is not recommended because lost tolerance raises the risk of fatal overdose afterwards.
  • B. Methadone is an effective alternative, but the CRISM guideline prefers buprenorphine-naloxone first when it is appropriate.
  • C. He has opioid use disorder and is in moderate withdrawal, so buprenorphine-naloxone can be started now without precipitating withdrawal. It is the preferred first-line treatment in the CRISM guideline.
  • D. Naltrexone is not first-line for opioid use disorder and would precipitate withdrawal if opioids remain in his system.
  • E. Clonidine eases some withdrawal symptoms but does not treat the disorder or lower overdose risk.

Opioid use disorder: offer opioid agonist therapy. Buprenorphine-naloxone first when appropriate, started once the patient is in moderate withdrawal; methadone if it is unsuitable. Add a naloxone kit.

Based on: CRISM National Guideline for the Clinical Management of Opioid Use Disorder

Example 2

A 54-year-old man is on day 2 after surgical fixation of a hip fracture. He is tremulous, sweating and anxious. Temperature 37.8 C, heart rate 116/min, blood pressure 164/94 mm Hg. He is oriented and has no hallucinations. His wife says he drinks about 10 beers a day. Liver enzymes are mildly raised, albumin and INR are normal. His CIWA-Ar score is 18. Thiamine has been given.

What is the most appropriate treatment?

Show answer and reasoning

Answer: A. Symptom-triggered oral diazepam

  • A. This is moderate to severe alcohol withdrawal. Benzodiazepines are the treatment, and symptom-triggered dosing with a long-acting agent such as diazepam suits a communicative patient with preserved liver function.
  • B. Haloperidol does not treat withdrawal, can lower the seizure threshold and may be used only as an adjunct for agitation already covered by benzodiazepines.
  • C. Gabapentin may help mild withdrawal in some outpatient settings but is not adequate alone for this score.
  • D. His score is high. The risk of seizures and delirium needs treatment now, not a delayed reassessment.
  • E. Beta blockers mask the signs used to guide dosing and do not prevent seizures or delirium tremens.

Alcohol withdrawal: benzodiazepines guided by CIWA-Ar, thiamine before glucose, and lorazepam or oxazepam when liver disease is significant or the patient is older.

Based on: CRISM guideline on high-risk drinking and alcohol use disorder; standard Canadian hospital practice

Example 3

A 16-year-old girl is seen after fainting in gym class. She has lost 11 kg over 5 months through restriction and running. Lying heart rate 42/min rising to 74/min on standing, blood pressure 82/50 mm Hg, temperature 35.4 C. Potassium is 3.0 mmol/L and phosphate is at the low end of normal. ECG shows sinus bradycardia. She says she is fine and wants to go home.

What is the most appropriate next step?

Show answer and reasoning

Answer: D. Hospital admission with cardiac monitoring

  • A. Family-based treatment is first-line for adolescent anorexia once she is medically stable, but she is not stable today.
  • B. Medication has little role in acute anorexia and does not address her medical instability.
  • C. Her low potassium matters, but bradycardia, hypotension, orthostatic change and hypothermia need monitored inpatient care.
  • D. Bradycardia, hypotension, a large orthostatic rise, hypothermia, syncope and hypokalemia show medical instability. She needs admission for monitoring, electrolyte replacement and cautious refeeding with phosphate checks.
  • E. Outpatient psychotherapy is part of long-term care but cannot manage the immediate cardiac and refeeding risks.

In eating disorders, decide medical stability first. Bradycardia, hypotension, orthostatic change, hypothermia, syncope or electrolyte disturbance mean admission and careful refeeding.

Based on: Canadian Paediatric Society position statement on eating disorders in adolescents

Example 4

A 31-year-old man with schizophrenia is brought to the emergency department by his group home staff. His haloperidol dose was increased 5 days ago. He is confused and mute. Temperature 39.6 C, heart rate 124/min, blood pressure 172/104 mm Hg and fluctuating. He has generalized lead-pipe rigidity and normal reflexes without clonus. CK is 18,400 U/L and creatinine 140 umol/L.

What is the most appropriate next step?

Show answer and reasoning

Answer: B. Stop haloperidol and begin supportive care

  • A. Benztropine treats acute dystonia, which causes sustained muscle spasm without fever, autonomic instability or a very high CK.
  • B. Fever, rigidity, autonomic instability, confusion and a high CK after a dose increase are neuroleptic malignant syndrome. The first step is to stop the antipsychotic and give supportive care: fluids, cooling and monitoring for renal injury.
  • C. Benzodiazepines can help in NMS, but continuing the causative drug keeps the syndrome going.
  • D. Any antipsychotic can cause NMS. Rechallenge is delayed until recovery and is done cautiously.
  • E. Serotonin syndrome causes clonus and hyperreflexia after serotonergic drugs. This patient has lead-pipe rigidity without clonus after a dopamine blocker.

Fever plus lead-pipe rigidity plus a high CK on an antipsychotic is NMS: stop the drug and support.

Based on: Standard toxicology and psychiatric practice for neuroleptic malignant syndrome

Example 5

A 45-year-old woman has been stable on methadone for opioid use disorder for 3 years. She now drinks 6 to 8 standard drinks a day and wants medication to help her cut down. She has no withdrawal symptoms between drinks. eGFR 88 mL/min/1.73 m2, AST 52 U/L, ALT 41 U/L, bilirubin normal. She is not pregnant.

Which treatment is most appropriate to offer?

Show answer and reasoning

Answer: E. Acamprosate with psychosocial support

  • A. Naltrexone is first-line for alcohol use disorder in general, but it is an opioid antagonist and will precipitate withdrawal and block methadone.
  • B. Disulfiram is not a first-line option in the CRISM alcohol guideline and carries hepatotoxicity and reaction risks.
  • C. Benzodiazepines are for withdrawal management, not ongoing cravings, and combining them with methadone and alcohol raises the risk of fatal overdose.
  • D. Stopping effective opioid agonist therapy raises the risk of relapse and overdose and is not needed to treat her drinking.
  • E. Acamprosate is a first-line option for alcohol use disorder, does not interact with opioids and is cleared by the kidneys, so it suits a patient on methadone with normal renal function.

Patient on opioids or opioid agonist therapy with alcohol use disorder: choose acamprosate, not naltrexone, and add psychosocial treatment.

Based on: CRISM Canadian guideline for the clinical management of high-risk drinking and alcohol use disorder

Quick recall

Tap a card to turn it over. If you can answer all of them without looking, move on to timed questions.

Where candidates lose marks

  • Detox is not treatment

    Withdrawal management alone for opioid use disorder raises overdose risk. The answer is opioid agonist therapy.

  • Too-early buprenorphine

    Giving buprenorphine to a patient not yet in withdrawal precipitates withdrawal. Check the time since last use and the COWS score.

  • Psychosis without a work-up

    New psychosis can be delirium, drugs or encephalitis. Exclude medical and substance causes before treating it as schizophrenia.

  • Haloperidol for withdrawal

    Antipsychotics do not treat alcohol withdrawal. Benzodiazepines do, with thiamine before glucose.

  • Sending the unstable home

    A thin adolescent with bradycardia and hypotension who says she feels fine still needs admission.

How to study psychosis & substance use

  1. Learn the duration rules for psychotic disorders and the organic causes of psychosis.

  2. Make one sheet on antipsychotic adverse effects: EPS, NMS, metabolic syndrome, prolactin, QT and clozapine monitoring.

  3. Read the summary of the CRISM opioid use disorder guideline and rehearse a buprenorphine start step by step.

  4. Draw the alcohol withdrawal timeline from tremor to delirium tremens and link each stage to its treatment.

  5. Review the CPS admission criteria for eating disorders and the refeeding electrolytes.

  6. Finish with 40 to 60 mixed questions from this question bank under timed conditions and review every explanation.

Practise psychosis & substance use free

Psychosis & Substance Use: questions candidates ask

Does the MCCQE expect me to know methadone and buprenorphine doses?

No. It expects the principles: buprenorphine-naloxone is preferred first-line when appropriate, methadone is the alternative, starts need moderate withdrawal or a low-dose approach, and withdrawal management alone is not recommended.

Is cannabis counselling different in Canada?

Yes. Cannabis is legal for adults, so counselling focuses on lower-risk use: delay first use, choose lower-THC products, avoid daily use and smoking, and never drive after use. Psychosis risk and youth use are key points.

How do I tell delirium tremens from a primary psychosis?

Delirium tremens comes two to three days after the last drink, with fluctuating attention, disorientation, fever and autonomic instability. Primary psychosis keeps orientation intact and has no withdrawal timeline.

Are eating disorders tested under psychiatry or pediatrics?

Both. The MCC blueprint is organized by dimensions of care and physician activities, so eating disorders appear in psychiatry, pediatrics and adolescent health items. The medical risk questions are the same in all of them.

Will the exam use US terms such as Suboxone waiver?

No. Canadian items use Canadian rules: no federal methadone exemption since 2018, opioid agonist therapy in primary care, slow-release oral morphine as an option, and naloxone without a prescription.

How do psychosis and substance use appear in the NAC Examination?

Mostly as history, counselling and management stations: a substance use history, a patient wanting help with opioids, new hallucinations, or a parent worried about weight loss. Examiners look for a structured, non-judgmental approach, a risk assessment for suicide and violence, and a clear plan. Oral questions often test first-line treatments.

Do I need to memorize each province's mental health act?

No. Know the shared principles: assessment and involuntary admission are possible when a mental disorder creates a risk of serious harm, capacity to consent to treatment is a separate decision, and patients have rights to information and review. Check the act for the province where you plan to practise.

Which smoking cessation medications should I know?

Nicotine replacement therapy, varenicline and bupropion are the first-line medications, offered together with counselling. Combination NRT, a patch plus a short-acting form, works better than one form alone. Remember that quitting smoking can raise clozapine and olanzapine levels.

Practise psychosis & substance use until the decisions are automatic

Free account, sample questions with full explanations. Upgrade only if it helps.

Start freeSee plans